Market Overview

Pluristem Receives Israeli Ministry of Health Approval to Initiate Phase II Study Using PLacental eXpanded

Pluristem Therapeutics (NASDAQ: PSTI) announced today that the Israeli Ministry of Health has approved the company's request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). This approval is part of the company's previously announced strategy to conduct a multi-national study for this indication. The protocol will be the same one used for the study previously approved in the U.S.

Zami Aberman, Chairman and CEO of Pluristem stated, "We are excited to receive the Ministry of Health approval for our clinical study in Israel. This also marks the first clinical study in Israel to use off-the-shelf allogeneic, placental-derived cells. Additionally, the professional review of this clinical trial application by the Israeli Ministry of Health will provide a solid foundation for Pluristem to conduct additional studies in Israel."

See full press release

Posted-In: News Guidance Financing Contracts Management Global

 

Most Popular

Related Articles (PSTI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free